Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2000 1
2004 1
2009 4
2010 2
2011 2
2012 6
2013 4
2014 8
2015 10
2016 16
2017 21
2018 20
2019 26
2020 21
2021 36
2022 41
2023 37
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives.
Chiu FY, Yen Y. Chiu FY, et al. Biomark Res. 2023 Mar 29;11(1):35. doi: 10.1186/s40364-023-00476-7. Biomark Res. 2023. PMID: 36991494 Free PMC article. Review.
Tumor changes in response to an intervention complement molecular and genomic translational diagnosis as well as quantitative information. ...An improved realization of cancer biology has transformed its management with an increasing emphasis on a personalized approach in …
Tumor changes in response to an intervention complement molecular and genomic translational diagnosis as well as quantitative informa …
Pharmacogenomics: current status and future perspectives.
Pirmohamed M. Pirmohamed M. Nat Rev Genet. 2023 Jun;24(6):350-362. doi: 10.1038/s41576-022-00572-8. Epub 2023 Jan 27. Nat Rev Genet. 2023. PMID: 36707729 Review.
Inter-individual variability in drug response, be it efficacy or safety, is common and likely to become an increasing problem globally given the growing elderly population requiring treatment. Reasons for this inter-individual variability include genomic factors, an area o …
Inter-individual variability in drug response, be it efficacy or safety, is common and likely to become an increasing problem globally given …
Implementing genomic medicine in the clinic: the future is here.
Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS. Manolio TA, et al. Genet Med. 2013 Apr;15(4):258-67. doi: 10.1038/gim.2012.157. Epub 2013 Jan 10. Genet Med. 2013. PMID: 23306799 Free PMC article. Review.
Several institutions have recently begun genomic medicine programs, encountering many of the same obstacles and developing the same solutions, often independently. ...Key infrastructure needs included an openly accessible knowledge base capturing sequence variants a …
Several institutions have recently begun genomic medicine programs, encountering many of the same obstacles and developing the …
Genomic profiling for clinical decision making in lymphoid neoplasms.
de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani RH, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman AL, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami G, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero JI, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose JM, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW. de Leval L, et al. Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854. Blood. 2022. PMID: 36001803 Free PMC article.
Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms …
Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities bei …
Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K, Taylor MD. Juraschka K, et al. J Neurosurg Pediatr. 2019 Oct 1;24(4):353-363. doi: 10.3171/2019.5.PEDS18381. J Neurosurg Pediatr. 2019. PMID: 31574483 Review.
With these recent discoveries in mind, the current state of medulloblastoma treatment and clinical trials is reviewed, including a novel risk stratification system that accounts for the molecular biomarkers of patients with a high risk for refractory disease. Lastly, criti …
With these recent discoveries in mind, the current state of medulloblastoma treatment and clinical trials is reviewed, including a no …
World Heart Federation Cholesterol Roadmap 2022.
Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, Almahmeed W, Alonso R, Daccord M, Ezhov M, Olmo RF, Jankowski P, Lanas F, Mehta R, Puri R, Wong ND, Wood D, Zhao D, Gidding SS, Virani SS, Lloyd-Jones D, Pinto F, Perel P, Santos RD. Ray KK, et al. Glob Heart. 2022 Oct 14;17(1):75. doi: 10.5334/gh.1154. eCollection 2022. Glob Heart. 2022. PMID: 36382159 Free PMC article. Review.
RESULTS: Reducing the future burden of ASCVD will require diverse approaches throughout the life-course. ...These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. …
RESULTS: Reducing the future burden of ASCVD will require diverse approaches throughout the life-course. ...These are preventable by …
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application.
Wang M, Song WM, Ming C, Wang Q, Zhou X, Xu P, Krek A, Yoon Y, Ho L, Orr ME, Yuan GC, Zhang B. Wang M, et al. Mol Neurodegener. 2022 Mar 2;17(1):17. doi: 10.1186/s13024-022-00517-z. Mol Neurodegener. 2022. PMID: 35236372 Free PMC article. Review.
Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration. Extensive clinical and genomic studies have revealed biomarkers, risk factors, pathways, and targets of AD in the past decade. ...W …
Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration. Exten …
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer.
Kudelova E, Smolar M, Holubekova V, Hornakova A, Dvorska D, Lucansky V, Koklesova L, Kudela E, Kubatka P. Kudelova E, et al. Int J Mol Sci. 2022 Nov 29;23(23):14937. doi: 10.3390/ijms232314937. Int J Mol Sci. 2022. PMID: 36499265 Free PMC article. Review.
Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological, and molecular levels. Genomic instability and greater mutation rates, which may result in the creation of neoantigens and enhanced immunogenicity, are additional characteris …
Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological, and molecular levels. Genomic ins …
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Kammermeier J, Lamb CA, Jones KDJ, Anderson CA, Baple EL, Bolton C, Braggins H, Coulter TI, Gilmour KC, Gregory V, Hambleton S, Hartley D, Hawthorne AB, Hearn S, Laurence A, Parkes M, Russell RK, Speight RA, Travis S, Wilson DC, Uhlig HH. Kammermeier J, et al. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):271-286. doi: 10.1016/S2468-1253(22)00337-5. Epub 2023 Jan 9. Lancet Gastroenterol Hepatol. 2023. PMID: 36634696 Review.
Genomic medicine enables the identification of patients with rare or ultra-rare monogenic forms of inflammatory bowel disease (IBD) and supports clinical decision making. ...Clear guidance and standardised, affordable applications of genomic technologi
Genomic medicine enables the identification of patients with rare or ultra-rare monogenic forms of inflammatory bowel disease
Implementing precision cancer medicine in the genomic era.
Chen HZ, Bonneville R, Roychowdhury S. Chen HZ, et al. Semin Cancer Biol. 2019 Apr;55:16-27. doi: 10.1016/j.semcancer.2018.05.009. Epub 2018 May 30. Semin Cancer Biol. 2019. PMID: 29857039 Review.
In this review, we will discuss different facets of utilizing genomic data to direct the increasingly complex care of cancer patients. We discuss the enlarging compendium of actionable genomic alterations and the development of novel molecular diagnostic assa …
In this review, we will discuss different facets of utilizing genomic data to direct the increasingly complex care of cancer p …
249 results